Sign In
Buy BCYC
$4.20
-0.1000 (-2.33%)
At Close: Jun 03, 2026
BCYC Stock: Why It Substantially Increased Today
09:49pm, Thursday, 07'th Oct 2021
The stock price of Bicycle Therapeutics PLC (NASDAQ: BCYC) increased by over 16% today. This is why it happened.
Bicycle Therapeutics Stock Falls After Interim Data Of Toxin Conjugates In Ovarian Cancer Trial
03:29pm, Thursday, 07'th Oct 2021
Bicycle Therapeutics plc (NASDAQ: BCYC) has reported interim Phase I trial results for BT5528 and preliminary findings from the ongoing dose-escalation portion of the BT8009 trial. Two BT5528 monot
3 Biotech Stocks That Soared to New Heights Last Week
06:21am, Sunday, 05'th Sep 2021
Find out what these industry favorites are doing to impress investors.
Bicycle Therapeutics: Scaffolding Short Linear Peptides Into Bicycles
05:02am, Wednesday, 25'th Aug 2021
Bicycle Therapeutics: Scaffolding Short Linear Peptides Into Bicycles
Ionis (IONS) Inks Deal With Bicycle Therapeutics for LICA Drugs
11:36am, Wednesday, 14'th Jul 2021
Ionis (IONS) signs a deal with Bicycle Therapeutics to incorporate the latter's optimized Bicycle peptides into its LICA delivery platform.
Bicycle, Ionis To Develop Targeted Oligonucleotide Therapeutics
08:06am, Tuesday, 13'th Jul 2021
Bicycle Therapeutics plc (NASDAQ: BCYC) announced that Ionis Pharmaceuticals Inc (NASDAQ: IONS) has exercised its option and entered into an exclusive worldwide license and collaboration agreement
Here's What Could Help Bicycle Therapeutics PLC Sponsored ADR (BCYC) Maintain Its Recent Price Strength
09:46am, Wednesday, 07'th Jul 2021
Bicycle Therapeutics PLC Sponsored ADR (BCYC) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several s
Bicycle Therapeutics Announces Restrictions on Shareholder Attendance at Annual General Meeting to be Held on June 28, 2021
04:30pm, Tuesday, 15'th Jun 2021
CAMBRIDGE, England, & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyc
Bicycle Therapeutics to Participate in Upcoming Virtual Investor Conferences
07:00am, Thursday, 27'th May 2021
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicycl
OXURION NV to Present at Wet AMD and DME Drug Development Summit
01:30am, Tuesday, 13'th Apr 2021
Leuven, BE, Boston, MA, US – April 13th, 2021 – 7.30 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care ophthalmic therapies,
Strength Seen in Bicycle Therapeutics PLC Sponsored ADR (BCYC): Can Its 5.9% Jump Turn into More Strength?
08:19am, Friday, 09'th Apr 2021
Bicycle Therapeutics PLC Sponsored ADR (BCYC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue movi
Oxurion is a leader in the development of pan-RGD integrin antagonists for retinal vascular disorders - THR-687 on track to enter Phase 2 development by mid-year
Oxurion NV enters into a Capital Commitment of up to €30 Million with Negma Group
01:30am, Tuesday, 06'th Apr 2021
Leuven, BE, Boston, MA, US – April 6, 2021 – 7.30 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care back of the eye therapies
OXURION to Participate in Upcoming Investor Meetings
01:30am, Wednesday, 31'st Mar 2021
Leuven, BE, Boston, MA, US – March 31st, 2021 – 07.30 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care ophthalmic therapies,
Bicycle Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
07:00am, Thursday, 11'th Mar 2021
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicycl
